| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 3,065 | 3,562 | ||
| Investments | 18,516 | 12,876 | ||
| Accounts receivable, net | 4,526 | 3,493 | ||
| Inventory | 7,049 | 8,633 | ||
| Prepaid expenses and other current assets | 5,378 | 3,098 | ||
| Restricted investments | 10,266 | 11,000 | ||
| Total current assets | 48,800 | 42,662 | ||
| Restricted cash | 0 | 0 | ||
| Property and equipment, net | 16,172 | 17,264 | ||
| Operating lease right-of-use assets | 3,497 | 3,772 | ||
| Finance lease right-of-use assets | 3,146 | 3,198 | ||
| Intangible assets, net | 5,685 | 7,025 | ||
| Other long-term assets | 1,762 | 2,089 | ||
| Total assets | 79,062 | 76,010 | ||
| Accounts payable | 5,990 | 6,244 | ||
| Accrued expenses | 4,706 | 3,405 | ||
| Contract liabilities | 1,180 | 1,165 | ||
| Operating lease liability | 1,025 | 1,348 | ||
| Finance lease liability | 251 | 254 | ||
| Convertible debentures payable (at fair value) | 9,825 | 11,762 | ||
| Total current liabilities | 22,977 | 24,178 | ||
| Operating lease liability, net of current portion | 2,599 | 2,704 | ||
| Finance lease liability, net of current portion | 3,495 | 3,511 | ||
| Long-term contract liabilities | 192 | 243 | ||
| Total liabilities | 29,263 | 30,636 | ||
| Common stock, 0.0001 par value, 400,000,000 shares authorized at september30, 2025 and december31, 2024 9,730,400 and 1,865,400 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 1 | - | ||
| Additional paid-in capital | 761,479 | 748,568 | ||
| Accumulated deficit | -711,687 | -703,184 | ||
| Accumulated other comprehensive income | 6 | -10 | ||
| Total stockholders equity | 49,799 | 45,374 | ||
| Total liabilities and stockholders equity | 79,062 | 76,010 | ||
Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)